Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

What this trial studies

Eligible subjects will have previously participated in the AXS-14-FM-301 (FORWARD) study. Subjects in this open-label extension trial will receive open-label AXS-14 for up to 52 weeks.

Who can join: the full rules

Inclusion Criteria:

* Participation in AXS-14-FM-301.

Exclusion Criteria:

* Unable to comply with study procedures.
* Medically inappropriate for study participation in the opinion of the Investigator.

Where it's running

• Clinical Research Site
  Little Rock, Arkansas, United States
• Clinical Research Site
  Anaheim, California, United States
• Clinical Research Site
  Oceanside, California, United States
• Clinical Research Site
  Redlands, California, United States
• Clinical Research Site
  Sacramento, California, United States
• Clinical Research Site
  Santa Ana, California, United States

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NMDA and Sigma-1 combination therapy for smoking cessation with AXS-05

  This phase 3 trial tests whether AXS-05 can help adults quit smoking better than placebo or bupropion.

  Recruiting at 28 sites Phase 3 Axsome Therapeutics, Inc. · Phoenix, Arizona and 27 other locations · NCT07766655

• Solriamfetol for ADHD in teens: see if it helps with focus

  This phase 3 study tests solriamfetol versus placebo in adolescents with ADHD to see if the medication improves symptoms over 6 weeks.

  Recruiting at 31 sites Phase 3 Axsome Therapeutics, Inc. · Dothan, Alabama and 30 other locations · NCT07717892

• Solriamfetol for children with ADHD: a 6-week comparison to placebo

  This trial tests whether solriamfetol can help children aged 6 to under 12 with ADHD, compared to placebo, over six weeks.

  Recruiting at 32 sites Phase 3 Axsome Therapeutics, Inc. · Dothan, Alabama and 31 other locations · NCT07717879

• Solriamfetol for major depression with excessive daytime sleepiness

  This trial will try solriamfetol (Sunosi) to reduce excessive daytime sleepiness in adults with major depressive disorder.

  Recruiting at 40 sites Phase 3 Axsome Therapeutics, Inc. · Tucson, Arizona and 39 other locations · NCT07484217

• Keeping fibromyalgia symptoms controlled with AXS-14 (esreboxetine) after an initial response

  This Phase 3 study will try AXS-14 (esreboxetine) in adults with fibromyalgia who respond to initial open treatment to see if continuing the drug keeps symptoms controlled better than switching to placebo.

  Recruiting at 57 sites Phase 3 Axsome Therapeutics, Inc. · Glendale, Arizona and 56 other locations · NCT07398417

• Evaluating Solriamfetol for Excessive Sleepiness in Shift Workers

  This study is testing if a new medication called solriamfetol can help adults with excessive sleepiness from shift work feel more awake and alert.

  Recruiting at 46 sites Phase 3 Axsome Therapeutics, Inc. · Auburn, Alabama and 48 other locations · NCT06568367

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.